|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013227,
umls-concept:C0045093,
umls-concept:C0178719,
umls-concept:C0205179,
umls-concept:C0205420,
umls-concept:C0243126,
umls-concept:C0278996,
umls-concept:C0851346,
umls-concept:C0920321,
umls-concept:C1517927,
umls-concept:C2603343
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2001-2-22
|
|
pubmed:abstractText |
To examine the feasibility and dose-limiting toxicity (DLT) of once-weekly gemcitabine at doses predicted in preclinical studies to produce radiosensitization, concurrent with a standard course of radiation for locally advanced head and neck cancer. Tumor incorporation of gemcitabine triphosphate (dFdCTP) was measured to assess whether adequate concentrations were achieved at each dose level.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:BradfordC RCR,
pubmed-author:ChepehaD BDB,
pubmed-author:DawsonL ALA,
pubmed-author:EisbruchAA,
pubmed-author:HogikyanN DND,
pubmed-author:LawrenceT STS,
pubmed-author:LittlerJ GJG,
pubmed-author:MarentetteL JLJ,
pubmed-author:ShewachD SDS,
pubmed-author:TeknosT NTN,
pubmed-author:TerrellJ EJE,
pubmed-author:UrayZZ,
pubmed-author:WolfG TGT
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
792-9
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:11157033-Adult,
pubmed-meshheading:11157033-Aged,
pubmed-meshheading:11157033-Aged, 80 and over,
pubmed-meshheading:11157033-Antimetabolites, Antineoplastic,
pubmed-meshheading:11157033-Biopsy,
pubmed-meshheading:11157033-Combined Modality Therapy,
pubmed-meshheading:11157033-Cytosine Nucleotides,
pubmed-meshheading:11157033-Deoxycytidine,
pubmed-meshheading:11157033-Dose-Response Relationship, Drug,
pubmed-meshheading:11157033-Drug Administration Schedule,
pubmed-meshheading:11157033-Female,
pubmed-meshheading:11157033-Head and Neck Neoplasms,
pubmed-meshheading:11157033-Humans,
pubmed-meshheading:11157033-Male,
pubmed-meshheading:11157033-Middle Aged,
pubmed-meshheading:11157033-Radiation-Sensitizing Agents,
pubmed-meshheading:11157033-Radiotherapy
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study.
|
|
pubmed:affiliation |
Departments of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, MI, USA. eisbruch@umich.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
